Patricia McGettigan1, Peter Roderick2, Abhay Kadam3, Allyson Pollock2. 1. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK. 2. Institute of Health and Society, Newcastle University, Newcastle upon Tyne, NE2 4AX, UK. 3. Lakshya Society for Public Health Education and Research, Pune, Maharashtra, India.
Abstract
AIMS: Rising antimicrobial resistance (AMR) is a global health crisis. India has among the highest resistance rates and antibiotic consumption internationally. Extensive use of fixed-dose combination (FDC) antibiotics and of unapproved formulations are claimed contributory factors but there has been no systematic examination of formulations or volumes sold. The aim of the present study was to investigate the regulatory approval status and sales volumes of systemic antibiotics marketed in India. METHODS: This was an ecological study using regulatory records in India, the UK and the US to determine the approval status in each country of systemic antibiotic FDCs and single-drug formulations (SDFs) sold in India. Pharmatrac® sales data were used to determine the formulations and volumes sold (2007-2012), branded-product numbers and manufacturers. RESULTS: Of 118 systemic antibiotic FDC formulations sold in India, 43 (36%) were approved but 75 (64%) had no record of regulatory approval; four (3%) formulations were approved in the UK and/or US. Almost half of formulations (58/118; 49%) comprised dual antimicrobials, most unapproved in India (43/58; 74%), and many were pharmacologically problematic. In contrast, 80/86 (93%) SDFs were approved in India and over two-thirds in the UK and/or US. Total antibiotic sales increased by 26%, from 2056 million units (2007-08) to 2583 million units (2011-12). FDC sales rose by 38% vs. 20% for SDFs. By 2011-12, FDCs comprised one-third of sales (872 million units). Over one-third of FDCs sold (300.26 million units; 34.5%) were of unapproved formulations. Multinational companies manufactured unapproved formulations and accounted for 19% of all FDC and SDF sales annually. CONCLUSIONS: Sales in India of antibiotic FDCs, including unapproved formulations, are rising. In the context of increasing AMR rates nationally and globally, unapproved antibiotic FDCs undermine India's national AMR strategy and should be banned from sale.
AIMS: Rising antimicrobial resistance (AMR) is a global health crisis. India has among the highest resistance rates and antibiotic consumption internationally. Extensive use of fixed-dose combination (FDC) antibiotics and of unapproved formulations are claimed contributory factors but there has been no systematic examination of formulations or volumes sold. The aim of the present study was to investigate the regulatory approval status and sales volumes of systemic antibiotics marketed in India. METHODS: This was an ecological study using regulatory records in India, the UK and the US to determine the approval status in each country of systemic antibiotic FDCs and single-drug formulations (SDFs) sold in India. Pharmatrac® sales data were used to determine the formulations and volumes sold (2007-2012), branded-product numbers and manufacturers. RESULTS: Of 118 systemic antibiotic FDC formulations sold in India, 43 (36%) were approved but 75 (64%) had no record of regulatory approval; four (3%) formulations were approved in the UK and/or US. Almost half of formulations (58/118; 49%) comprised dual antimicrobials, most unapproved in India (43/58; 74%), and many were pharmacologically problematic. In contrast, 80/86 (93%) SDFs were approved in India and over two-thirds in the UK and/or US. Total antibiotic sales increased by 26%, from 2056 million units (2007-08) to 2583 million units (2011-12). FDC sales rose by 38% vs. 20% for SDFs. By 2011-12, FDCs comprised one-third of sales (872 million units). Over one-third of FDCs sold (300.26 million units; 34.5%) were of unapproved formulations. Multinational companies manufactured unapproved formulations and accounted for 19% of all FDC and SDF sales annually. CONCLUSIONS: Sales in India of antibiotic FDCs, including unapproved formulations, are rising. In the context of increasing AMR rates nationally and globally, unapproved antibiotic FDCs undermine India's national AMR strategy and should be banned from sale.
Authors: Christine Årdal; Kevin Outterson; Steven J Hoffman; Abdul Ghafur; Mike Sharland; Nisha Ranganathan; Richard Smith; Anna Zorzet; Jennifer Cohn; Didier Pittet; Nils Daulaire; Chantal Morel; Zain Rizvi; Manica Balasegaram; Osman A Dar; David L Heymann; Alison H Holmes; Luke S P Moore; Ramanan Laxminarayan; Marc Mendelson; John-Arne Røttingen Journal: Lancet Date: 2015-11-18 Impact factor: 79.321
Authors: Thomas P Van Boeckel; Sumanth Gandra; Ashvin Ashok; Quentin Caudron; Bryan T Grenfell; Simon A Levin; Ramanan Laxminarayan Journal: Lancet Infect Dis Date: 2014-07-09 Impact factor: 25.071
Authors: Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi Journal: Clin Infect Dis Date: 2016-05-15 Impact factor: 9.079
Authors: Brian G Bell; Francois Schellevis; Ellen Stobberingh; Herman Goossens; Mike Pringle Journal: BMC Infect Dis Date: 2014-01-09 Impact factor: 3.090
Authors: Osman A Dar; Rumina Hasan; Jørgen Schlundt; Stephan Harbarth; Grazia Caleo; Fazal K Dar; Jasper Littmann; Mark Rweyemamu; Emmeline J Buckley; Mohammed Shahid; Richard Kock; Henry Lishi Li; Haydar Giha; Mishal Khan; Anthony D So; Khalid M Bindayna; Anthony Kessel; Hanne Bak Pedersen; Govin Permanand; Alimuddin Zumla; John-Arne Røttingen; David L Heymann Journal: Lancet Date: 2015-11-18 Impact factor: 79.321
Authors: Alison H Holmes; Luke S P Moore; Arnfinn Sundsfjord; Martin Steinbakk; Sadie Regmi; Abhilasha Karkey; Philippe J Guerin; Laura J V Piddock Journal: Lancet Date: 2015-11-18 Impact factor: 79.321
Authors: Barbara Bortone; Charlotte Jackson; Yingfen Hsia; Julia Bielicki; Nicola Magrini; Mike Sharland Journal: PLoS One Date: 2021-01-20 Impact factor: 3.240